BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition

Nature

Volumn 473, Issue 7347, 2011, Pages 384-391

  Duy, Cihangir ^a,b   Hurtz, Christian ^a,f   Shojaee, Seyedmehdi ^a   Cerchietti, Leandro ^c   Geng, Huimin ^c   Swaminathan, Srividya ^a   Klemm, Lars ^a   Kweon, Soo Mi ^b   Nahar, Rahul ^a,b   Braig, Melanie ^d   Park, Eugene ^b   Kim, Yong Mi ^b   Hofmann, Wolf Karsten ^e   Herzog, Sebastian ^f   Jumaa, Hassan ^f   Koeffler, H Phillip ^g   Yu, J Jessica ^h   Heisterkamp, Nora ^b   Graeber, Thomas G ⁱ   Wu, Hong ⁱ   Ye, B Hilda ^h   Melnick, Ari ^c   Müschen, Markus ^a,b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; JANUS KINASE 2; NILOTINIB; PROTEIN BCL 6; PROTEIN INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RETRO INVERSO BCL 6 PEPTIDE INHIBITOR; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ENZYME ACTIVITY; INHIBITION; MUTAGENICITY; SIGNAL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA DAMAGE; DRUG RESISTANCE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; UPREGULATION;

ADP-RIBOSYLATION FACTOR 1; ANIMALS; CELL SURVIVAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79956305728     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09883     Document Type: Article

References (45)

1. Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001). (Pubitemid 32267973)
2. Armstrong, S. A. et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3, 173-183 (2003). (Pubitemid 37443389)
3. Meydan, N. et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379, 645-648 (1996). (Pubitemid 26053453)
4. Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004). (Pubitemid 38938156)
5. O'Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401-412 (2009).
6. Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive toSTI571 in vitro. Blood 99, 319-325 (2002).
7. Naka, K. et al. TGF-b-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463, 676-680 (2010).
8. Oravecz-Wilson, K. I. et al. Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell 16, 137-148 (2009).
9. Saito M.,et al. Asignaling pathway mediating downregulation ofBCL6ingerminal center B cellsisblocked byBCL6 gene alterationsinB cell lymphoma. Cancer Cell 12, 280-292 (2007). (Pubitemid 47333420)
10. Pratilas, C. A. et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl Acad. Sci. USA 106, 4519-4524 (2009).
11. Choudhary, C. et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol. Cell 36, 326-339 (2009).
12. Janes, M. R. et al. Effective and selective targeting of leukemia cells using a TORC1/ 2 kinase inhibitor. Nature Med. 16, 205-213 (2010).
13. Walker, S. R., Nelson, E. A. & Frank, D. A. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 26, 224-233 (2007). (Pubitemid 46095733)
14. Duy, C. et al. BCL6 is critical for the development of a diverse primary B cell repertoire. J. Exp. Med. 207, 1209-1221 (2010).
15. Fernandez de Mattos, S. et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol. Cell. Biol. 24, 10058-10071 (2004).
16. Phan, R. T. & Dalla-Favera, R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432, 635-639 (2004). (Pubitemid 39626271)
17. Wendel, H. G. et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc. Natl Acad. Sci. USA 103, 7444-7449 (2006).
18. Goldberg, Z., Levav, Y., Krichevsky, S., Fibach, E. & Haupt, Y. Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage. Cell Cycle 3, 1188-1195 (2004). (Pubitemid 40268638)
19. Skorta, I. et al. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl1 cells by differential modulation of p53 transcriptional and proapoptotic activity. Cancer Res. 69, 9337-9345 (2009).
20. Kamijo, T. et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659 (1997). (Pubitemid 27513656)
21. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665 (2005). (Pubitemid 41117262)
22. Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377-1380 (2008). (Pubitemid 352775249)
23. Williams,R.T., Roussel,M.F. &Sherr,C.J.Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 103, 6688-6693 (2006).
24. Krause, D. S., Lazarides, K., von Andrian, U. H. & Van Etten, R. A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nature Med. 12, 1175-1180 (2006). (Pubitemid 44527353)
25. Cerchietti, L. C. et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 113, 3397-3405 (2009).
26. Shaffer, A. L. et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13, 199-212 (2000).
27. Williams, R. T. den, B. W. & Sherr, C. J. Cytokine-dependent imatinib resistance in mouse BCR-ABL1, Arf-null lymphoblastic leukemia. Genes Dev. 21, 2283-2287 (2007). (Pubitemid 47443334)
28. Gruber, T. A., Chang, M. S., Sposto, R. & Muschen, M. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Res. 70, 7411-7420 (2010).
29. Cerchietti, L. C. et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17, 400-411 (2010).
30. Pear, W. S. et al. Efficient and rapid induction of a chronic myelogenous leukemialike myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92, 3780-3792 (1998). (Pubitemid 28525205)
31. Onishi, M. et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol. Cell. Biol. 18, 3871-3879 (1998). (Pubitemid 28287910)
32. Godar,S.etal. Growth-inhibitoryandtumor-suppressive functionsofp53 depend on its repression of CD44 expression. Cell 134, 62-73 (2008). (Pubitemid 351905743)
33. Kumar,M. S.etal. Dicer1 functionsas ahaploinsufficient tumor suppressor. Genes Dev. 23, 2700-2704 (2009).
34. Soneoka,Y.etal. Atransientthree-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 23, 628-633 (1995).
35. Dent, A. L., Shaffer, A. L., Yu, X., Allman, D. & Staudt, L. M. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276, 589-592 (1997). (Pubitemid 27193682)
36. Ye, B. H. et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nature Genet. 16, 161-170 (1997).
37. Cui,Y.etal. InactivationofStat5inmousemammaryepitheliumduringpregnancy reveals distinct functionsin cell proliferation, survival, and differentiation. Mol. Cell. Biol. 24, 8037-8047 (2004). (Pubitemid 39167454)
38. Groszer M.etal. Negative regulationofneural stem/progenitor cellproliferation by the Pten tumor suppressor gene in vivo. Science 294, 2186-2189 (2001). (Pubitemid 33150679)
39. Ahmad, K.F. et al. Mechanism ofSMRT corepressor recruitment bythe BCL6 BTB domain. Mol. Cell 12, 1551-1564 (2003). (Pubitemid 38037022)
40. Ghetu, A. F. et al. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. Mol. Cell 29, 384-391 (2008). (Pubitemid 351215940)
41. Polo, J. M. et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nature Med. 10, 1329-1335 (2004). (Pubitemid 40022714)
42. Chakravarti, L. Roy,(1967).HandbookofMethodsofApplied Statistics, VolumeI, John Wiley and Sons, pp. 392-394. (1967).
43. Ci, W. et al. The BCL6 transcriptional program features repression of multiple oncogenesinprimaryBcells andisderegulatedinDLBCL.Blood113, 5536-5548 (2009).
44. Polo, J. M. et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc. Natl Acad. Sci. USA 104, 3207-3212 (2007). (Pubitemid 46364138)
45. Trageser, D. et al. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J. Exp. Med. 206, 1739-1753 (2009).